Modulation of Nicotinic Receptors in Neurons in the Common Snail by Noopept and Piracetam
The nootropic agents noopept and piracetam alter the amplitudes of acetylcholine-induced influx currents (ACh currents) in command neurons in the common snail. Both compounds have cholinopositive activity. The dose curve of the actions of noopept is bell-shaped, while the piracetam dose-response curve in the range of physiological concentrations shows a monotonous rise. Noopept increases the ACh current at low concentrations (10–10–10–8 M), while piracetam acts at significantly higher concentrations (starting from 10–4 M). The magnitudes of the maximal cholinopositive effects of noopept and piracetam (in the range of physiological concentrations) were identical, while the concentrations of nootropic drugs at which they were reached differed by seven orders of magnitude. The half-maximal concentration (EC50) of noopept was 10–10 M and that of piracetam was 10–3 M. The mechanisms of the cholinopositive actions of these drugs are discussed.
Keywordsacetylcholine noopept piracetam dose–effect relationships
Unable to display preview. Download preview PDF.
- Bering, B. and Müller, W. E., “Interaction of piracetam with several neurotransmitter receptors in the central nervous system,” Drug Res., 35, 1350–1352 (1985).Google Scholar
- Boiko, S. S., Korotkov, S. A., Zherdev, V. P., et al., “Pharmacokinetics and BBB permeability of a novel acylprolinedipeptide with nootropic properties after oral administration,” Byull. Eksperim. Biol. Med., 129, No. 4, 426–429 (2000).Google Scholar
- Bulatov, V. V., Khokhoev, T. Kh., Dikii, V. V., et al., “The problems of small and supersmall doses in toxicology. Basic and applied aspects,” Ros Khim. Zh., XLVI, No. 6, 58–62 (2002).Google Scholar
- Gudasheva, T. A. and Skoldinov, A. P., “A strategy for creating dipeptide neuropsychotropic drugs,” Eksperim. Klin. Farmakol., 66, No. 2, 15–19 (2003).Google Scholar
- Gudasheva, T. A., “A strategy for the creation of dipeptide drugs,” Vestn. Ross. Akad. Med. Nauk., 7, 8–16 (2011).Google Scholar
- Ierusalimskii, V. N., Zakharov, I. S., Palikhova, T. A., and Balaban, P. M., “The nervous system and neuron mapping in the gastropod mollusk Helix lucorum, L.,” Zh. Vyssh. Nerv. Deyat., 42, No. 6, 1075–1089 (1992).Google Scholar
- Leuner, K., Kurz, Ch., Guidetti, G., et al., “Improved mitochondrial function in brain aging and Alzheimer disease -the new mechanism of action of the old metabolic enhancer piracetam,” Front. Neurosci., 4, Art. 44 (2010), doi 10.3389/fnins.2010.00044.Google Scholar
- Lombardo, S. and Maskos, U., “Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment,” Neuropharmacology, 96, part B, 255–262 (2015), doi https://doi.org/10.1016/j.neuropharm.
- Murzina, G. B., “The effects of lateral diffusion of receptors on depression of neuron cholinosensitivity,” Biofizika, 58, No. 3, 516–523 (2013).Google Scholar
- Ostrovskaya, R. U., Gudasheva, T. A., Voronina, T. A., and Seredenin, S. B., “The original nootropic and neuroprotective drug noopept (GVS-111),” Eksp. Farm. Toksikol., 5, 66–73 (2002).Google Scholar
- Ostrovskaya, R. U., Mirzoev, T. Kh., Firova, F. A., et al., “Behavioral and electrophysiological analysis of the cholinopositive action of the nootropic acylproline dipeptide GVS-111,” Eksp. Klinich. Farmakol., 64, No. 2, 11–14 (2001).Google Scholar
- Ostrovskaya, R. U., Tsaplina, A. P., Vakhitova, Yu. V., et al., “Efficacy of the nootropic and neuroprotective dipeptide noopept in a streptozotocin model of Alzheimer’s disease in rats,” Eksp. Klinich. Farmakol., 73, No. 12, 2–5 (2010).Google Scholar
- Ostrovskaya, R. U., Vakhitova, Y. V., Kuzmina, U. Sh., et al., “Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation,” J. Biomed. Sci., 6, No. 21, 74 (2014), doi: 10.1186/s12929-014-0074-2.Google Scholar
- Pepeu, G. and Spignoli, G., “Nootropic drugs and brain cholinergic mechanisms,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 13, Supplement, S77–S88 (1989).Google Scholar
- Pilch, H. and Müller, W. E., “Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice,” Psychopharmacology, 9, No. 4, 74–78 (1988).Google Scholar
- Pivovarov, A. S. and Drozdova, E. I., “Identification of cholinoreceptors on the bodies of RPa3 and LPa3 neurons in the common snail,” Neirofiziologiya, 24, No. 1, 77–86 (1992).Google Scholar
- Pivovarov, A. S., “Cholinoreceptors of neurons in the common snail: identification, plasticity, and its regulation by opioids and second messengers,” Zh. Vyssh. Nerv. Deyat., 42, No. 6, 1271–1286 (1992).Google Scholar
- Pivovarov, A. S., Ostrovskaya, R. U., Drozdova, E. I., and Saakyan, S. A., “The effects of piracetam on acclimation of the cholinoreceptor membrane in the common snail,” Byull. Eksperim. Biol. Med., 104, No. 7, 51–53 (1987).Google Scholar
- Radionova, K. S., Bel’nik, A. P., and Ostrovskaya, R. U., “The original nootropic drug ‘Noopept’ eliminates memory defects induced by blockade of muscarinic and nicotinic cholinoreceptors in rats,” Byull. Eksperim. Biol. Med., 146, No. 7, 65–68 (2008).Google Scholar
- Zherdev, V. P., Boiko, S. S., Neznamov, G. G., et al., “Clinical pharmacokinetics of noopept in patients with intellectual-mnestic disorders,” Klinich. Farmakokin., 2, No. 2, 49–52 (2005).Google Scholar